NewGenIvf Group Ltd has made a significant move by announcing a reverse stock split, which will reduce the number of its outstanding shares. This decision is aimed at enhancing the company's marketability and potentially attracting more institutional investors.
The reverse stock split will take effect at 12:01 a.m. (ET) on October 23, 2026. Following this split, the company's Class A Ordinary Shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market. The trading symbol will remain as "NIVF," but the shares will have a new CUSIP number: G0544E162.
Currently, NewGenIvf has approximately 9,821,197 Class A Ordinary Shares outstanding. After the reverse split, this number is expected to decrease to about 1,227,650 shares, as every eight shares will be consolidated into one. Importantly, no fractional shares will be issued; instead, shareholders entitled to fractional shares will receive one full share.
This move follows the company's recent strategic efforts to streamline its capital structure. The reverse stock split is authorized under the BVI Business Companies Act, allowing the Board of Directors to implement it without requiring shareholder approval.
NewGenIvf Group Ltd operates in the health services sector, specifically categorized under Services-Misc Health & Allied Services, NEC. This reverse stock split could position the company more favorably within the industry, aligning it with peers that have successfully navigated similar corporate actions.
The company’s decision reflects a broader trend in the health services industry, where firms often seek to consolidate shares to enhance their stock's perceived value and attract institutional investment. This action may also indicate NewGenIvf’s commitment to improving its market position and shareholder value.
Looking ahead, the filing does not specify what further actions the company may take post-split, but the management’s focus on enhancing shareholder value is clear.